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BSJ: Before we talk about how the body perceives the world, how have you perceived the world throughout your life? 
Did you see yourself studying somatosensation early on in your 
academic career? What about your path to Berkeley has surprised 
you?
DB: I started out as a fine arts major. I took a number of years to figure out that I was more interested in studying 
science as an academic pursuit and potentially as a career. As an 
undergraduate, when I was working in the lab, I became more 
interested in science and experiments. I worked in a lab that was 
studying basic mechanisms of phototransduction, vision, and 
how light gets converted into an electrical signal. I just really 
liked neuroscience and the idea that you can take something that 
everybody can relate to and experience and try to understand it at 
a molecular and cellular level—like how we perceive light. To me, 
that was really exciting, that something so fundamental could be 
looked at. As an undergraduate, in real time, I was able to shine 
light on a photoreceptor and record the electrical signal. That was 
really amazing to me. I didn’t know any scientists growing up, so 
it was an introduction to science and doing research. Working 
in that lab as a work-study student, I found out about graduate 
school and how you can get paid to go to graduate school and 
do science, and that work inspired me to go into biology and 
neuroscience. I didn’t study somatosensation until I was a 
postdoc. I studied ion channels when I was in graduate school 
at Stanford, but then I wanted to go back to studying sensory 
systems. So, I went back to that initial love of processing real 
world signals by the nervous system for my postdoc at UCSF.
BSJ: So going from ion channels to somatosensation was a natural next step.
DB: Yeah, it was a way to still look at ion channels and excitability in the nervous system, but then bring it back 
to how we interact with the outside world. For me, it’s still really 
interesting.
Dr. Diana Bautista is an Associate Professor of Cell 
and Developmental Biology and Affiliate of the Division 
of Neurobiology in the Department of Molecular and Cell 
Biology and the Helen Wills Neuroscience Institute at the 
University of California, Berkeley.  Professor Bautista’s 
research focuses on using molecular, cellular, and physiological 
approaches to investigate how humans perceive and 
distinguish between pain and itch.  In this interview, we 
discuss her findings on the importance of the sphingosine 
1-phosphate (S1P) signaling pathway in mechanosensation.
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detect touch, so we decided to do the same types of experiments 
that a neurologist might do to assess sensitivity and patience. 
We could do the same thing in mice that either have a normal 
functioning gene or have a gene mutated, such that it no longer is 
expressed. We can touch the mouse’s paw with a gentle probe or 
with a probe that applies more force, and we can ask, how much 
force does it take for the paw to withdraw? We would predict 
that the wild-type mice would have a regular response. Then, we 
can compare them to the knockout mice that have no functional 
copies of these genes being expressed. We can also compare them 
to the heterozygous mice that have one functional copy of the 
gene and display an intermediate phenotype. We found that the 
heterozygous phenotype looks just like the wild type, but that the 
mutant mice were very different. They didn’t respond normally.
BSJ: You also explored this effect through pharmacological means.  Why did you inject mice with both S1PR3- 
and SIPR1-selective antagonists?
DB: We wanted to see how specific the S1PR3 receptor is. We injected some mice with S1PR3 antagonist to 
see if it affected touch. We also injected the S1PR1 antagonist 
as a control experiment, because some people have suggested 
that S1PR1 might be important as well. However, we didn’t 
see any effect by S1PR1 when we looked at mechanical pain. 
But when we used the S1PR3 antagonist, we did see an effect. 
Scientists always want to test things in multiple ways. Maybe the 
mouse had a developmental defect that didn’t really have to do 
with sensing, such that it could no longer process information 
normally. So being able to put in an acute pharmacological agent 
and see the same effect really suggests that it’s an active process. 
Another cool thing is that these S1PR3 inhibitors had been 
tested in humans. Not for pain, but for other unrelated 
things, so we knew that they were safe. It was exciting 
to use a drug that was potentially safe to use in humans.
BSJ: When S1P levels of mice were decreased by injection of the inhibitor SKI II, you found that they had reduced 
mechanical sensitivity.  Were you able to recover mechanical 
sensitivity by injecting exogenous S1P into these mice?  
DB: We used an enzyme, the SKI II inhibitor, which blocks production of S1P. We saw reduced sensitivity, 
suggesting that active production of this lipid, S1P, mediates 
this response. We also injected different amounts of exogenous 
S1P directly back in after we got rid of the normal S1P that’s 
being produced. Then, we could generate a dose response of 
how the response changes at different concentrations of S1P.
BSJ: What does it mean to activate a cell in response to neuronal stimulation? 
DB: For you to see light or hear a sound or feel a touch, your nervous system has to become activated. 
Your nervous system communicates with your body through 
electrical signals, so when we say neurons get activated, 
we mean that there’s some type of trigger that causes
an electrical signal to run through that neuron. The activation 
could be a variety of different things, but we are particularly 
interested in how neurons get activated by physical stimuli and the 
outside world. Consequently, we study touch and pain, such as the 
brush of a feather or the prick of a pin. These are the mechanical 
forces that activate neurons and trigger electrical signals directly.
BSJ: What is the difference between noxious tactile stimuli and innocuous tactile stimuli? 
DB: Noxious stimuli are stimuli that are capable of causing tissue damage, while innocuous stimuli 
generally do not. An innocuous stimulus isn’t as painful or 
irritating as a noxious stimulus. If I poked you with a pin, you 
would probably say that it’s a noxious stimulus, whereas if I 
brushed you with a feather, it would be gentle. You know the 
weight of your clothes is innocuous because when you put your 
clothes on, you might feel them, but then you just don’t really 
think about them the rest of the day. We’re interested in how 
cells respond to both noxious and innocuous signals like that, 
and how under conditions of disease, our responses change.
BSJ: You investigated the role of sphingosine 1-phosphate (S1P) and S1P Receptor 3 (S1PR3) in mechanical 
pain.  What are S1P and S1PR3?  Overall, how did the responses 
of S1PR3 knockout mice differ from those of wild-type and 
heterozygous mice?
DB: We are very interested in the molecules that allow us to detect the difference between noxious and innocuous 
stimuli. We did a screen for candidate genes that encode proteins 
that are involved in mechanotransduction, the act of converting 
a mechanical force into an electrical signal, and S1PR3 was one 
of our candidate molecules. It turns out that this is a G-protein-
coupled receptor that binds to a signaling lipid. Our hypothesis 
was that when this protein gets activated, it opens an ion 
channel that generates an electrical signal and modulates how 
we experience touch. However, we didn’t know if it modulates 
noxious or innocuous touch, so we obtained S1PR3 knockout 
mice. Nobody had looked at this animal in terms of its ability to 
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BSJ: What did that show you about S1P? How does it operate at baseline levels, and how does it activate 
S1PR3 for functional mechanical sensitivity?
DB: There seemed to be a range of S1P levels in the skin that give rise to different types of pain. Under normal 
conditions, it seems to be important for normal sensitivity to 
mechanical pain: you bump your knee, or you touch a cactus, 
and you move away. If you turn the S1P down, then you lose 
sensitivity, similar to diabetic neuropathy, where you don’t feel 
as well. If you put really high levels in—abnormally high—you 
become hypersensitive to pain. It was a continuum. It’s often 
called the rheostat, where you get a continuum of different 
phenotypes. So, at baseline levels, you have normal responses 
to pain, which are important protective reflexes. But if you turn 
it down or up, then you get these really extreme conditions that 
aren’t good. For example, loss of tactile sensitivity in diabetic 
neuropathy causes repetitive injuries that cause tissue damage, 
and eventually, in many patients, amputations. High levels of 
S1P could cause hypersensitivity to pain, which is associated 
with lots of different chronic conditions. If you actually go 
to the literature, people have measured high levels of S1P 
in patients with really severe arthritis pain, suggesting that 
elevated S1P might be a disease related to different pain diseases.
BSJ: Your study largely employs a type of neuron called the dorsal root ganglion (DRG). What is the significance 
of these neurons in the body?
DB: The DRG neurons in both humans and mice are a distinct cluster of neurons alongside your spinal 
cord that innervate your body from the neck down. They 
allow you to feel temperature and mechanical sensations. If 
you get poison oak when hiking, these are the neurons that 
get activated that make you itchy. They also innervate the gut 
and the lungs and are involved in interoception—detection 
of stimuli within your body. When you get a stomach ache, 
or if you have asthma or lung irritation from smoke, these 
are the neurons that signal. They are the sensory system 
for the outside world as well as for the inside of the body.
BSJ: In a similar vein, what are mechanonociceptors and nociceptors, and what distinguishes A 
mechanonociceptors (AMs) from C nociceptors? 
DB: Your somatosensory neurons come in different flavors. Half are dedicated to gentle touch and proprioception, 
which is the awareness of limb position. These neurons are all 
mechanosensitive. They are the ones that innervate the skin and 
allow you to feel the brush of a feather or vibration. When you 
touch something, they’ll let you feel that there’s an edge and 
distinguish what the shapes are. The ones in your muscles are 
also sensing muscle tension. Half of your DRG somatosensory 
neurons are dedicated to those senses. The other half are dedicated 
to pain. There are fast pain neurons—when you stub your toe, if 
you count to three, you’re going to feel that “ouch”! Those are the 
A deltas that mediate noxious mechanical pain. Then you have 
Figure 1: Schematic for S1P-mediated AM activation. Under baseline conditions, 
S1P mediates the normal response to mechanical stimuli via AMs.2  
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Figure 2:  Schematic  for S1P-mediated activation of the pain pathway versus the 
itch pathway.  The subset of neurons co-expressing TRPV1 and S1PR3 mediate 
the pain response, while the subset of neurons co-expressing TRPA1 and S1PR3 
mediate the itch response.3
C fiber nociceptors, and those are a little bit slower. If you have 
a cut, you might notice that there’s a red  weal of sensitivity that 
surrounds the cut. That’s mediated by the slower-pain C fibers. 
These are the same ones that get activated if you squirt lemon 
in your eye and it feels painful. They detect noxious mechanical 
pressure, temperature, and chemicals. The C fibers also respond 
to capsaicin, menthol, wasabi, and Szechuan peppercorn. So 
AMs and C nociceptors have somewhat overlapping and distinct 
functions in pain.  
BSJ: How did you determine the localization of S1PR3 in C nociceptors and AMs?
DB: We used a variety of different techniques. We had RNA sequencing data, so we knew what types of 
transcripts were expressed in different subsets of neurons. 
We also used antibodies against the protein to see what 
types of cell subsets it’s expressed in, and we stained with 
other markers that we know of for these different subtypes 
of pain versus touch. We also used in situ hybridization to 
fluorescently label the mRNA. So, we looked at mRNA in 
two different ways and looked at proteins using fluorescence.
BSJ: You found that high levels of S1P activate C nociceptors and not AMs.  What does this finding 
suggest about their respective roles in mechanosensation? 
DB: It’s a little complicated, because we found that, under baseline levels, 
AMs were activated. 100 nanomolar is the 
typical concentration of S1P in the body 
under normal conditions—a very low level 
of S1P. The AM nociceptors were playing 
an important homeostatic role in keeping 
excitability in check and maintaining normal 
sensitivity (Fig. 1). Then we elevated S1P 
concentration to that of disease levels, around 
one micromolar. We saw a preferential 
activation of C nociceptors. Normally, C 
nociceptors are not active, but under these 
conditions, they activated without any 
stimuli, which is a concern. 
BSJ: You found that S1PR3 is implicated in our perception of 
itch in addition to mechanical pain. Now 
that we’ve discussed nociceptors, what is a 
prurireceptor? 
DB: Prurireceptors are itch receptors. The name comes from “pruritis,” which means itchy.  A subset of the 
C fibers that were previously classified as just pain receptors 
also mediate itch. There are a lot of inflammatory mediators 
that trigger itch in some conditions and trigger pain in others. 
One common example is histamine. If you get a mosquito 
bite, that makes you itchy—wherever histamine is released 
in your skin, it preferentially activates itch receptors. But in 
some chronic pain conditions, histamine can become elevated 
in a different part of the skin, where it activates pain neurons. 
We found that depending on where S1P gets elevated in 
different disease conditions, it can trigger itch instead of pain.
BSJ: Could you briefly describe for our readers what TRP channels are?  What is the difference between TRPA 
and TRPV channels? 
DB: TRP channels stands for transient receptor potential ion channels. It’s a family of ion channels that has 
about 30 members broadly expressed throughout the body. 
TRPV1 is a particular ion channel that is activated by capsaicin 
(the active component in chili peppers), heat, and different 
inflammatory mediators. It plays an important role in pain and 
temperature sensation. In a subset of cells, it can also contribute 
to histamine-dependent itch signaling. So TRPV1 is the heat 
and capsaicin receptor. If you delete that receptor, there’s 
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a deficit in thermal pain and an inability to detect capsaicin. 
The TRPA1 ion channel is a relative of TRPV1, but it is activated 
by many different inflammatory mediators both found in the 
body and the environment—for example, reactive oxygen species, 
markers of inflammation, or disease-activated markers in the 
body. It’s also activated by wasabi. When you feel that pungent 
wasabi next time you eat sushi, it’s because you’re activating 
the TRPA1 ion channel on the free nerve endings in your 
mouth. However, it’s very short-lived, so you don’t trigger a big 
inflammatory response when you just eat sushi. You would need 
high levels of TRPA1 activation to cause pain and inflammation.
BSJ: What differences did you find between S1P signaling via S1PR3 in prurireceptors versus nociceptors?  What 
role do the TRPA1 and TRPV1 channels play in our perception 
of pain versus itch?
DB: We found that there are many different kinds of neurons that express TRPA1 and TRPV1. There’s 
a subset of them that are co-expressed with S1PR3. The 
subset of TRPA1-S1PR3 neurons are a small population 
that trigger the itch pathway when activated. The subset 
of TRPV1-S1PR3 neurons gives rise to inflammatory pain 
when activated (Fig. 2). These different subsets get activated 
in different parts of the skin under varying conditions.
BSJ: You collaborated with scientists to generate a synthetic, “photoswitchable” analogue of S1P called 
PhotoS1P.  What does it mean to be “photoswitchable”?
DB: We had a really cool collaboration with Dirk Trauner’s lab. They are chemists who are interested in a lot of 
interesting biological molecules, including signaling lipids 
like S1P. They engineered the lipid itself so that it had an extra 
chemical moiety that was very sensitive to light. This moiety 
keeps the signaling molecule in a locked conformation under 
normal light. If you hit the molecule with a certain wavelength 
of light, it causes a conformational change that now makes 
that lipid accessible and able to signal (Fig. 3). We injected 
this engineered S1P into mice and put it into cells, and it 
didn’t do anything until we zapped it with light. It then sprang 
into action and could trigger neuronal activation or reflexive 
behaviors in the animal very rapidly, as if we were poking it.
BSJ: How does the stability of Photo-S1P make it easier to control for sphingolipid metabolism, and what 
implication does this have for future academic and clinical studies? 
Figure 3: Structure of PhotoS1P. On the left is PhotoSph, the 
precursor of PhotoS1P.  The two molecules to the right demonstrate 
photoswitching between the cis and trans isomers of PhotoS1P, 
induced by 365 nm or 465 nm light.4
DB: Right now, it’s a really amazing tool. Lipids are notoriously hard to control. They’re produced all 
the time. There aren’t a lot of specific tools to manipulate 
them. So it was really amazing to be able to turn on 
and off whatever amount of S1P we wanted to. That is 
not something that’s easy to do. S1P is becoming a very 
important signaling lipid in the nervous system. It’s not just 
in the pain pathway, where abnormally high levels are linked to 
disease. S1P is also thought to be elevated in the hippocampus and 
in Alzheimer’s patients, so I think it could be a really important 
tool to figure out all of the diverse roles that this very important 
signaling lipid has under normal and disease conditions. 
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